Actinium's Scientific Advisory Board Endorses and Supports the Iomab-B Phase 3 Clinical Trial Development Program Dec 9, 2014
Experts in Leukemia Treatment Support Ongoing Phase 1/2 Study of Actinium's Actimab-A, a Low Intensity Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Ages 60 and Older Dec 8, 2014
Actinium Receives Orphan-Drug Designation From FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients Dec 1, 2014
Actinium Clinical Advisory Board Chair to Participate in the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Nov 11, 2014
Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 Months in Elderly Secondary Acute Myeloid Leukemia Nov 6, 2014
Actinium Announces Collaboration With Albert Einstein College of Medicine on New Actinium Program Oct 27, 2014
Final Reminder Related to Actinium's Key Opinion Leader Event Focused on Emerging Therapies for Acute Myeloid Leukemia on October 21st in New York City Oct 20, 2014
Actinium to Host Key Opinion Leader Event Focused on Emerging Therapies for Acute Myeloid Leukemia on October 21 in New York City Oct 14, 2014
Actinium to Present at the 14th Annual Biotech in Europe Forum for Global Partnering and Investment on September 30th Sep 25, 2014